Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 3, 2017BJU International

Prognostic value of urinary prostate cancer antigen 3 (PCA3) during active surveillance of patients with low‐risk prostate cancer receiving 5α‐reductase inhibitors

View Full Paper
Ask AI
Bookmark
Share

Authors

VFVincent FradetCentre hospitalier universitaire de QuébecPTPaul TorenChildren's Mercy HospitalMNMolière Nguilé-MakaoInserm

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Fradet et al. (2017) studied this question.

synapsesocial.com/papers/6a9b83c5d6bcd4d1ccf4fa43https://doi.org/10.1111/bju.14041
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Long-Term Follow-Up of a Large Active Surveillance Cohort of Patients With Prostate Cancer2014 · 1,232 citations
  2. 2Pathological Upgrading and Up Staging With Immediate Repeat Biopsy in Patients Eligible for Active Surveillance2008 · 282 citations
  3. 3APTIMA PCA3 Molecular Urine Test: Development of a Method to Aid in the Diagnosis of Prostate Cancer2006 · 532 citations